REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I
- Tuesday, December 1, 2020, 7:10
- Business
- Add a comment
ROCKVILLE, Md., Dec. 1, 2020 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that the first patient has…
About the Author
adminasapcorp has written 38957 stories on this site.